Skip to main content
NIH funding notice PAR-21-024

HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)

Closed on March 15, 2023.

Posted
September 3, 2020
Close date
March 15, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $8,376,131 in first-year total cost, median $4,188,066.

Most frequent study sections

  1. Special Emphasis Panel[ZAI1 JBS-A (S1)]1
  2. Special Emphasis Panel[ZAI1 VS-A (S1)]1

Most frequent institutions

  1. CALIFORNIA INSTITUTE OF TECHNOLOGY1
  2. UNIVERSITY OF PENNSYLVANIA1
Competing awards under PAR-21-024 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies2P01AI100148-11BJORKMAN, PAMELA JHAHN, BEATRICE HNUSSENZWEIG, MICHEL CCALIFORNIA INSTITUTE OF TECHNOLOGY, CA$4,197,323ZAI1
2022SHIV Env-antibody coevolution as a molecular guide to HIV-1 V3 glycan targeted vaccine design2P01AI131251-06SHAW, GEORGE MUNIVERSITY OF PENNSYLVANIA, PA$4,178,808ZAI1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.